Expression of Preferentially Expressed Antigen in Melanoma, a Cancer/Testis Antigen, in Carcinoma In Situ of the Urinary Tract

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2023 Dec 22

PMID 38132219

Authors

Shota Fujii

Mitsuaki Ishida

Kazumasa Komura

Kazuki Nishimura

Takuya Tsujino

Tomohito Saito

Yohei Taniguchi

Tomohiro Murakawa

Haruhito Azuma

Yoshinobu Hirose

Affiliations

Soon will be listed here.

Abstract

Carcinoma in situ (CIS) of the urinary tract comprises 1-3% of all urothelial malignancies and is often a precursor to muscle-invasive urothelial carcinoma (UC). This study aimed to examine the expression profiles of preferentially expressed antigen in melanoma (PRAME), a cancer/testis antigen, and assess its diagnostic and therapeutic applications in CIS, given that its expression in UC has been minimally studied and has not yet been analyzed in CIS. We selected consecutive patients with CIS who underwent biopsy and/or transurethral tumor resection at the Osaka Medical and Pharmaceutical University Hospital. Immunohistochemical staining for PRAME and p53 was performed. Overall, 53 patients with CIS (6 females and 47 males) were included. Notably, PRAME expression was observed in 23 of the 53 patients (43.4%), whereas it was absent in the non-neoplastic urothelial epithelium. Furthermore, no correlation was found between PRAME expression and aberrant p53 expression. Therefore, PRAME expression may serve as a useful marker for CIS of the urinary tract. Furthermore, PRAME may be a candidate for the novel therapeutic target for standard treatment-refractory CIS patients.

References

Nguyen J, Przybycin C, McKenney J, Magi-Galluzzi C . Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap. Hum Pathol. 2020; 98:81-88. DOI: 10.1016/j.humpath.2020.02.008. View

Iura K, Kohashi K, Hotokebuchi Y, Ishii T, Maekawa A, Yamada Y . Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. J Pathol Clin Res. 2016; 1(3):144-59. PMC: 4939879. DOI: 10.1002/cjp2.16. View

Koh S, Lau S, Scapa J, Cassarino D . PRAME immunohistochemistry of spitzoid neoplasms. J Cutan Pathol. 2022; 49(8):709-716. DOI: 10.1111/cup.14245. View

Tessari A, Pilla L, Silvia D, Duca M, Paolini B, Carcangiu M . Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?. Breast. 2018; 42:68-73. DOI: 10.1016/j.breast.2018.08.106. View

Kim J, Choi J, Kim Y . Comparison of Melanocyte-Associated Immunohistochemical Markers in Acral Lentiginous Melanoma and Acral Benign Nevi. Am J Dermatopathol. 2023; 45(11):748-752. DOI: 10.1097/DAD.0000000000002555. View

Subiela J, Faba O, Guerrero Ramos F, Vila Reyes H, Pisano F, Breda A . Carcinoma In Situ of the Urinary Bladder: A Systematic Review of Current Knowledge Regarding Detection, Treatment, and Outcomes. Eur Urol Focus. 2019; 6(4):674-682. DOI: 10.1016/j.euf.2019.03.012. View

Cazzato G, Cascardi E, Colagrande A, Belsito V, Lospalluti L, Foti C . PRAME Immunoexpression in 275 Cutaneous Melanocytic Lesions: A Double Institutional Experience. Diagnostics (Basel). 2022; 12(9). PMC: 9498170. DOI: 10.3390/diagnostics12092197. View

Iura K, Maekawa A, Kohashi K, Ishii T, Bekki H, Otsuka H . Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1. Hum Pathol. 2016; 61:130-139. DOI: 10.1016/j.humpath.2016.12.006. View

Oyama K, Kanki K, Shimizu H, Kono Y, Azumi J, Toriguchi K . Impact of Preferentially Expressed Antigen of Melanoma on the Prognosis of Hepatocellular Carcinoma. Gastrointest Tumors. 2017; 3(3-4):128-135. PMC: 5465675. DOI: 10.1159/000448137. View

10.

Rasic D, Korsgaard N, Marcussen N, Precht Jensen E . Diagnostic utility of combining PRAME and HMB-45 stains in primary melanocytic tumors. Ann Diagn Pathol. 2023; 67:152211. DOI: 10.1016/j.anndiagpath.2023.152211. View

11.

Bahmad H, Oh K, Alexis J . Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma. J Cutan Pathol. 2023; 50(8):763-772. DOI: 10.1111/cup.14438. View

12.

Brohl A, Sindiri S, Wei J, Milewski D, Chou H, Song Y . Immuno-transcriptomic profiling of extracranial pediatric solid malignancies. Cell Rep. 2021; 37(8):110047. PMC: 8642810. DOI: 10.1016/j.celrep.2021.110047. View

13.

Nettersheim D, Arndt I, Sharma R, Riesenberg S, Jostes S, Schneider S . The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas. Br J Cancer. 2016; 115(4):454-64. PMC: 4985348. DOI: 10.1038/bjc.2016.187. View

14.

Neal D, Amin M, Smith S . CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia. Diagn Pathol. 2020; 15(1):61. PMC: 7251721. DOI: 10.1186/s13000-020-00984-2. View

15.

Doolan P, Clynes M, Kennedy S, Mehta J, Crown J, ODriscoll L . Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat. 2007; 109(2):359-65. DOI: 10.1007/s10549-007-9643-3. View

16.

Tanaka N, Wang Y, Shiseki M, Takanashi M, Motoji T . Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells. Leuk Res. 2011; 35(9):1219-25. DOI: 10.1016/j.leukres.2011.04.005. View

17.

Pan S, Su K, Spiessens B, Kusuma N, Delahaye N, Gruselle O . Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non-small cell lung cancer patients. Asia Pac J Clin Oncol. 2016; 13(5):e212-e223. DOI: 10.1111/ajco.12586. View

18.

Le M, Vuong H, Dunn I, Kondo T . Molecular and clinicopathological implications of PRAME expression in adult glioma. PLoS One. 2023; 18(10):e0290542. PMC: 10553321. DOI: 10.1371/journal.pone.0290542. View

19.

Ricci C, Franceschini T, Giunchi F, Grillini M, Ambrosi F, Massari F . Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia In Situ, and Germ Cell Tumors of the Testis. Am J Clin Pathol. 2021; 157(5):644-648. DOI: 10.1093/ajcp/aqab200. View

20.

Zhang W, Li L, Cai L, Liang Y, Xu J, Liu Y . Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the receptor protein of CRL2 complex. Cell Death Differ. 2021; 28(6):1926-1940. PMC: 8184998. DOI: 10.1038/s41418-020-00724-5. View